As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Emicizumab for the treatment of haemophilia A.
This review discusses its pharmacological properties, dosage and administration, efficacy and tolerability, and evidence in support of the use of Emicizumab as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Huyen Tran, a clinical & laboratory haematologist and current Head of Haemostasis & Thrombosis Unit, and Director of the Haemophilia Centre, at The Alfred Hospital.
Please login below to download this issue (PDF)